Company Information

  

Address: 75 PARK PLAZA
4TH FLOOR 
City: BOSTON 
State: MA 
Zip Code: 02116 
Telephone: (617) 807-6600 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics based upon tetracycline chemistry. We have used our expertise in biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the minocycline core structure. Our two lead product candidates are the antibacterials omadacycline and sarecycline. We have generated innovative small molecule therapeutic candidates based upon medicinal chemistry-based modifications, according to structure-based activity, of all positions of the core tetracycline molecule. These efforts have yielded molecules with broad-spectrum antibiotic properties and narrow-spectrum antibiotic properties, and molecules with potent anti-inflammatory properties to fit specific therapeutic applications.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-3.09NAN/E
12/2017-3.32NAN/E
09/2017-3.66NAN/E
06/2017-3.82NAN/E
03/2017-4.87NAN/E
12/2016-5.51NAN/E
09/2016-5.60NAN/E
06/2016-6.05NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.16Total Liab/Total Assets0.50
Net Inc/Total Assets-0.54Total Liab/Inv Cap0.55
Net Inc/Inv Cap-0.61Total Liab/Comm Equity0.15
Pretax Inc/Net Sales-7.00Interest Coverage Ratio-16.39
Net Inc/Net Sales-7.06Curr Debt/EquityNA
Cash Flow/Net Sales-6.23LTD/Equity0.72
SG&A/NetSales2.88Total Debt/Equity0.72
Asset Utilization   Liquidity  
Net Receivables Turnover4.06Quick Ratio9.56
Inventory TurnoverNACurrent Ratio9.56
Inventory Day SalesNANet Rec/Curr Assets0.04
Net Sales/Work Cap0.09Inv/Curr AssetsNA
Net Sales/PP&E7.37  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.01 5.07 0.01 7.51
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 11.86 11.65 8.20 8.40
Operating Income -26.71 -20.87 -20.30 -16.65
Interest Exp 1.51 1.41 1.41 1.13
Pretax Income -27.75 -21.89 -21.32 -17.43
Other Income 0.47 0.39 0.38 0.34
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -27.75 -21.89 -21.32 -18.18

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 184.55 151.89 163.60 175.45
Receivables - Total 0.84 5.89 0.00 0.02
Inventories - Total NA NA NA NA
Total Current Assets 188.23 160.49 166.21 178.44
Net Property, Plant & Equipment 1.58 1.71 1.92 2.04
Total Assets 191.29 163.70 169.73 182.13
Liabilities        
Accounts Payable 15.76 16.79 15.80 15.03
Debt in Current Liabilities 7.61 NA NA NA
Total Current Liabilities 23.37 16.79 15.80 15.03
Long-Term Debt 51.68 59.19 49.08 48.98
Total Liabilities 80.53 81.22 69.86 68.75
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -497.86 -470.11 -448.22 -426.90
Treasury Stock NA NA NA NA
Total Stockholders' Equity 110.77 82.48 99.87 113.38
Total Liabilities and Stockholders' Equity 191.29 163.70 169.73 182.13

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -19.05 -22.39 -15.50 -15.76
Net Cash Provided by Investing Activities -18.72 14.11 -6.80 -45.75
Net Cash Provided by Financing Activities 51.69 10.69 3.71 51.74

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.48-4.65--
12/20144.34-17.84-7.82
12/20150.00-70.86-4.29
12/20160.03-111.64-5.51
12/201712.62-89.07-3.32
Growth Rates126.66----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1814125,57580.94




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.